{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:52:46Z","timestamp":1760057566502,"version":"build-2065373602"},"reference-count":43,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: According to Globocan, Romania has the highest incidence of nasopharyngeal cancer (NPC) in Europe. Our objective was to evaluate the survival data for a cohort of non-Asian patient population treated with curative intent at a tertiary cancer center in Romania. Methods: We retrospectively analyzed 161 patients with histologically proven, non-metastatic NPC treated at our institution between October 2014 and December 2021 with intensity modulated arc radiotherapy (IMRT) with or without neoadjuvant or concomitant chemotherapy according to the stage of the disease. Kaplan-Meier estimates of overall, disease-free, locoregional relapse free and distant metastasis free survival were calculated. The log-rank test was used to determine significant prognostic determinants of overall and disease-free survival. Results: The median age was 50 years (range 19\u201380), 88% had nonkeratinizing undifferentiated carcinoma. Epstein Barr virus status was not evaluated routinely. 42.2% of patients were stage III and 46% stage IVA disease. Induction chemotherapy was prescribed for 72.7% of patients and 89.4% received concurrent chemotherapy. After a median follow up of 44 months (range: 3.6, 104.7 months), the estimated 3 years overall, disease free, locoregional relapse free and distant metastasis free survival of the entire cohort were 82.6%, 73.3%, 83.2% and 86.3% respectively. On testing interactions, concomitant chemotherapy offered significant survival benefit (HR\u20140.287; 95% CI 0.137\u20130.603; p = 0.001) and cumulative Cisplatin dose of more than 100 mg\/mp was statistically significant for survival (HR\u20140.350;95% CI 0.157\u20130.779; p = 0.01) Conclusions: This is the largest retrospective series of nasopharyngeal cancer from Romania reporting survival data. Despite the high percentage of advanced stage disease our data shows very good disease control. Compliance to optimal concomitant chemotherapy should represent a priority in clinical practice in a non-Asian patient population.<\/jats:p>","DOI":"10.3390\/jcm14041177","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T10:53:22Z","timestamp":1739271202000},"page":"1177","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes for Nasopharyngeal Cancer in Non-Asian Patients: A Single-Center Experience"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3217-0630","authenticated-orcid":false,"given":"Renata","family":"Zahu","sequence":"first","affiliation":[{"name":"Department of Oncology and Radiotherapy, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania"},{"name":"Amethyst Radiotherapy Center Cluj, 407280 Flore\u0219ti, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Urian","sequence":"additional","affiliation":[{"name":"Amethyst Radiotherapy Center Cluj, 407280 Flore\u0219ti, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlad","family":"Manolescu","sequence":"additional","affiliation":[{"name":"Amethyst Radiotherapy Center Cluj, 407280 Flore\u0219ti, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei","family":"Ungureanu","sequence":"additional","affiliation":[{"name":"Amethyst Radiotherapy Center Cluj, 407280 Flore\u0219ti, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Bodale","sequence":"additional","affiliation":[{"name":"Amethyst Radiotherapy Center Cluj, 407280 Flore\u0219ti, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5274-0017","authenticated-orcid":false,"given":"Alexandru","family":"Iacob","sequence":"additional","affiliation":[{"name":"Amethyst Radiotherapy Center Cluj, 407280 Flore\u0219ti, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan Cristian","family":"Vesa","sequence":"additional","affiliation":[{"name":"Department 2 Functional Sciences, Discipline of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Tiple","sequence":"additional","affiliation":[{"name":"Department of ENT, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2245-3302","authenticated-orcid":false,"given":"Gabriel","family":"Kacso","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapy, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania"},{"name":"Amethyst Radiotherapy Center Cluj, 407280 Flore\u0219ti, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1158\/1055-9965.EPI-20-1702","article-title":"The Evolving Epidemiology of Nasopharyngeal Carcinoma","volume":"30","author":"Chang","year":"2021","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1002\/cam4.4783","article-title":"The global, regional, national burden of nasopharyngeal cancer and its attributable risk factors (1990\u20132019) and predictions to 2035","volume":"11","author":"Song","year":"2022","journal-title":"Cancer Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Su, Z.Y., Siak, P.Y., Leong, C.-O., and Cheah, S.-C. (2023). The role of Epstein\u2013Barr virus in nasopharyngeal carcinoma. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1116143"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/0194599816672625","article-title":"Racial and Ethnic Disparities in Nasopharyngeal Cancer Survival in the United States: A SEER Study","volume":"156","author":"Patel","year":"2017","journal-title":"Otolaryngol.\u2013Head Neck Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/COC.0000000000000091","article-title":"Asian Versus Non-Asian Outcomes in Nasopharyngeal Carcinoma: A North American Population-based Analysis","volume":"39","author":"Hamilton","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099","volume":"16","author":"LeBlanc","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2016.67.4119","article-title":"What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis","volume":"35","author":"Marguet","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0360-3016(02)02724-4","article-title":"Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: An update of the UCSF experience","volume":"53","author":"Lee","year":"2002","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e49968","DOI":"10.2196\/49968","article-title":"Nasopharyngeal Cancer Incidence and Mortality in 185 Countries in 2020 and the Projected Burden in 2040: Population-Based Global Epidemiological Profiling","volume":"9","author":"Zhang","year":"2023","journal-title":"JMIR Public Health Surveill."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"vi333","DOI":"10.1093\/annonc\/mdw376.18","article-title":"Mutation profiles of nasopharyngeal carcinomas in South-Eastern European patients","volume":"27","author":"Fountzilas","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Marin, M.A., Closca, R.-M., Marin, A., Rakitovan, M., Nicoara, A., Poenaru, M., Militaru, M., and Baderca, F. (2024). Clinical, Epidemiological, Morphological, and Immunohistochemical Aspects of Nasopharyngeal Carcinoma-4-Year Retrospective Study in the Western Part of Romania. Diagnostics, 14.","DOI":"10.3390\/diagnostics14070722"},{"key":"ref_14","first-page":"640","article-title":"Nasopharyngeal carcinoma\u2014Analysis of risk factors and immunological markers","volume":"107","author":"Anghel","year":"2012","journal-title":"Chirurgia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejca.2021.05.022","article-title":"A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma","volume":"153","author":"Lee","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2023.10.004","article-title":"Tumor molecular landscape of Epstein-Barr virus (EBV) related nasopharyngeal carcinoma in EBV-endemic and non-endemic areas: Implications for improving treatment modalities","volume":"265","author":"Lenoci","year":"2024","journal-title":"Transl. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2018.77.7847","article-title":"Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial","volume":"36","author":"Chan","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40880-019-0385-5","article-title":"Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma","volume":"39","author":"Zhang","year":"2019","journal-title":"Cancer Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ejca.2021.09.005","article-title":"Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort","volume":"159","author":"Bossi","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1479-5876-10-57","article-title":"Further evidence for the existence of major susceptibility of nasopharyngeal carcinoma in the region near HLA-A locus in Southern Chinese","volume":"10","author":"Zhao","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2174\/156652409788970698","article-title":"HLA Associations with Nasopharyngeal Carcinoma","volume":"9","author":"Li","year":"2009","journal-title":"Curr. Mol. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1479-5876-5-22","article-title":"Associations between HLA Class I alleles and the prevalence of nasopharyngeal carcinoma (NPC) among Tunisians","volume":"5","author":"Li","year":"2007","journal-title":"J. Transl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1002\/cncr.34266","article-title":"Clinical presentation and outcome of human papillomavirus-positive nasopharyngeal carcinoma in a North American cohort","volume":"128","author":"Huang","year":"2022","journal-title":"Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.amjoto.2019.06.007","article-title":"HPV status in patients with nasopharyngeal carcinoma in the United States: A SEER database study","volume":"40","author":"Wotman","year":"2019","journal-title":"Am. J. Otolaryngol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hed.25450","article-title":"Epstein-Barr virus and human papillomaviruses as favorable prognostic factors in nasopharyngeal carcinoma: A nationwide study in Finland","volume":"41","author":"Ruuskanen","year":"2019","journal-title":"Head Neck"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hed.27333","article-title":"A multicenter retrospective analysis of patients with nasopharyngeal carcinoma treated in IMRT era from a nonendemic population: Turkish Society for Radiation Oncology Head and Neck Cancer Group Study (TROD 01-001)","volume":"45","author":"Yildirim","year":"2023","journal-title":"Head Neck"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clon.2019.11.009","article-title":"A Multicentre UK Study of Outcomes of Nasopharyngeal Carcinoma Treated With Intensity-Modulated Radiotherapy \u00b1 Chemotherapy","volume":"32","author":"Slevin","year":"2020","journal-title":"Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.oraloncology.2017.12.004","article-title":"Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study)","volume":"77","author":"Au","year":"2018","journal-title":"Oral Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejca.2017.01.002","article-title":"Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial","volume":"75","author":"Chen","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e41278","DOI":"10.1097\/MD.0000000000041278","article-title":"Comparison of TPF and PF induction chemotherapy combined with cisplatin concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A systematic review and meta-analysis","volume":"104","author":"Li","year":"2025","journal-title":"Medicine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2019.07.007","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase III multicentre randomised controlled trial","volume":"119","author":"Yang","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(23)00163-8","article-title":"Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): An updated individual patient data network meta-analysis","volume":"24","author":"Petit","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_34","first-page":"59","article-title":"Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients","volume":"32","author":"Blanchard","year":"2022","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/annonc\/mdr116","article-title":"Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: A randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation","volume":"23","author":"Fountzilas","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.oraloncology.2016.10.011","article-title":"Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma","volume":"62","author":"Ou","year":"2016","journal-title":"Oral Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(15)70126-9","article-title":"Chemotherapy and radiotherapy in nasopharyngeal carcinoma: An update of the MAC-NPC meta-analysis","volume":"16","author":"Blanchard","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s44178-023-00040-1","article-title":"CACA guidelines for holistic integrative management of nasopharyngeal carcinoma","volume":"2","author":"Tang","year":"2023","journal-title":"Holist. Integr. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.7150\/jca.19725","article-title":"Who benefited most from higher cumulative dose of cisplatin among patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiation therapy? A retrospective study of 527 cases","volume":"8","author":"Ou","year":"2017","journal-title":"J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Peng, H., Chen, L., Li, W.-F., Guo, R., Mao, Y.-P., Zhang, Y., Zhang, F., Liu, L.-Z., Tian, L., and Lin, A.-H. (2016). The Cumulative Cisplatin Dose Affects the Long-Term Survival Outcomes of Patients with Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy. Sci. Rep., 6.","DOI":"10.1038\/srep24332"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.oraloncology.2015.08.005","article-title":"Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis","volume":"51","author":"Zhang","year":"2015","journal-title":"Oral Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/bjc.2013.720","article-title":"Late toxicities after intensity-modulated radiotherapy for nasopharyngeal carcinoma: Patient and treatment-related risk factors","volume":"110","author":"Zeng","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40463-022-00593-7","article-title":"Longitudinal functional outcomes and late effects of radiation following treatment of nasopharyngeal carcinoma: Secondary analysis of a prospective cohort study","volume":"51","author":"Gill","year":"2022","journal-title":"J. Otolaryngol. Head Neck Surg."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/4\/1177\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:31:24Z","timestamp":1760027484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/4\/1177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["jcm14041177"],"URL":"https:\/\/doi.org\/10.3390\/jcm14041177","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2025,2,11]]}}}